4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued on Thursday,Weiss Ratings reports.

FDMT has been the topic of a number of other reports. Chardan Capital decreased their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a report on Monday, January 13th. Leerink Partners cut their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Finally, Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $26.71.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock remained flat at $3.34 on Thursday. 271,455 shares of the stock traded hands, compared to its average volume of 831,400. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The company's fifty day moving average price is $3.62 and its 200-day moving average price is $5.62. The company has a market capitalization of $154.65 million, a PE ratio of -1.17 and a beta of 2.89.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10). As a group, equities research analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the business. Barclays PLC increased its stake in 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company's stock worth $1,241,000 after buying an additional 67,202 shares during the period. Rhumbline Advisers increased its position in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after acquiring an additional 3,675 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of 4D Molecular Therapeutics by 139.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock valued at $364,000 after acquiring an additional 38,031 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after purchasing an additional 92,791 shares during the period. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.